Anlotinib Combined With TACE in Hepatocellular Carcinoma Patients at High Risk of Post Surgery Recurrence

Inclusion Criteria: * Patients participate in the study voluntarily and sign informed consent with good compliance. * After hepatectomy, satisfy any of the following recurrence factors was assessed:≥5 cm and \< 10 cm of tumor diameter; tumor number≥3; tumor microvascular invasion grade M1; portal vein carcinoma thrombus resection(Ⅰ、Ⅱ). * Histological or cytological confirmation of hepatocellular carcinoma, or at least two imaging tests with hepatocellular carcinoma characteristics, or one imaging test with hepatocellular carcinoma characteristics and AFP \> 400μg/L. * TACE treatment (cTACE only) was completed within 1-2 months after hepatectomy. * ≥ 18 and ≤ 75 years of age. * ECOG performance status of 0-1. * liver function child-Pugh class A or B (≤7 points). * Except for hepatectomy, no previous tumor-related treatment was received, and the remaining liver was assessed to have good liver function. Exclusion Criteria: * Patients who have had or are currently complicated with other malignant tumors,or recurrent hepatocellular carcinoma (\>10 mm)in baseline data or in TACE. * Patients with absolute contraindications to TACE. * Patients with HCV infection. * Urine protein ≥ ++，and 24-hour urinary protein excretion\>1.0 g confirmed. * Pregnant or lactating women. * Patients with mental illness.